清華程京院士課題組采用我司硅羧基磁珠PMSi300003提取咽拭子檢測新冠

Sensitive and Rapid Diagnosis of Respiratory Virus Coinfection Using a Microfluidic Chip-Powered CRISPR/Cas12a System

使用微流控芯片驅動的 CRISPR/Cas12a 系統靈敏快速地診斷呼吸道病毒感染
Jiajia Liu,Huili Wang,Li Zhang,Ying Lu,Xu Wang,Minjie Shen,Nan Li,Li Feng,Juhui Jing,Bin Cao,Xiaohui Zou,Jing Cheng,Youchun Xu
First published: 22 May 2022 https://doi.org/10.1002/smll.202200854


Abstract
The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 is profoundly influencing the global healthcare system and people's daily lives. The high resource consumption of coronavirus disease 2019 (COVID-19) is resulting in insufficient surveillance of coinfection or resurgence of other critical respiratory epidemics, which is of public concern. To facilitate evaluation of the current coinfection situation, a microfluidic system (MAPnavi) is developed for the rapid (<40?min) and sensitive diagnosis of multiple respiratory viruses from swab samples in a fully sealed and automated manner, in which a nested-recombinase polymerase amplification and the CRISPR-based amplification system is first proposed to ensure the sensitivity and specificity. This novel system has a remarkably low limit of detection (50–200 copies mL?1) and is successfully applied to detect 171 clinical samples (98.5% positive predictive agreement; 100% negative predictive agreement), and the results identify 45.6% coinfection among clinical samples from patients with COVID-19. This approach has the potential to shift diagnostic and surveillance efforts from targeted testing for a high-priority virus to comprehensive testing of multiple virus sets and to greatly benefit the implementation of decentralized testing.

摘要 

      由嚴重急性呼吸綜合征冠狀病毒 2 引起的持續大流行正在深刻影響全球醫療保健系統和人們的日常生活。 2019 年冠狀病毒病 (COVID-19) 的高資源消耗導致對合并感染或其他嚴重呼吸道傳染病復發的監測不足，這是公眾關注的問題。為了便于評估當前的共感染情況，開發了一種微流控系統 (MAPnavi)，用于以完全密封和自動化的方式快速（<40?min）和靈敏地診斷拭子樣本中的多種呼吸道病毒，其中嵌套重組酶聚合酶首次提出了基于CRISPR的擴增系統，以確保靈敏度和特異性。這種新型系統具有非常低的檢測限（50-200 拷貝 mL-1），并成功應用于檢測 171 個臨床樣本（98.5% 的陽性預測一致性；100% 的陰性預測一致性），結果確定了 45.6% 的共感染來自 COVID-19 患者的臨床樣本。這種方法有可能將診斷和監測工作從針對高優先級病毒的針對性測試轉變為對多個病毒集的全面測試，并極大地有利于分散測試的實施。

本論文所采用的磁珠：http://www.sdxsdw.com/Product/267584288.html